One-shot immunization with Sputnik Light (the first component of Sputnik V vaccine) is effective against SARS-CoV-2 Delta variant: efficacy data on the use of the vaccine in civil circulation in Moscow
Authors: Dolzhikova Inna V , Gushchin Vladimir A , Shcheblyakov Dmitry V , Tsybin Alexander N. , Shchetinin Alexey M , Pochtovyi Andrey A , Komissarov Andrey B , Kleymenov Denis A. , Kuznetsova Nadezhda A , Tukhvatulin Amir I , Zubkova Olga V , Dzharullaeva Alina S , Kovyrshina Anna V , Lubenets Nadezhda L , Grousova Daria M , Erokhova Alina S , Izhaeva Fatima M , Popova Olga , Ozharovskaya Tatiana A , Semikhin Alexander S , Tokarskaya Elizaveta A , Shmarov Maksim M , Nikitenko Natalia A , Shidlovskaya Elena V , Bykonia Evgeniia N. , Mazunina Elena P. , Divisenko Elizaveta V , Vasilchenko Lyudmila A , Popova Liubov I. , Danilenko Daria M , Lioznov Dmitry A , Tkachuk Artem P , Borisevich Sergei V , Naroditsky Boris S , Logunov Denis Y , Gintsburg Alexander L 
Published: October 2021

Objectives

Vaccination remains the most effective response to the COVID-19 pandemic. Most vaccines use two-dose regimens. In turn, single-dose vaccines also have high potential, since, on the one hand, they simplify the vaccination program, make it more accessible and convenient for more people around the world, and on the other hand, they are better suited for subsequent revaccination. However, there is not enough data on the effectiveness of single-dose vaccine variants against new genetic lines to assess their current potential. It is not clear how much a single dose of immunization protects against the globally dominant delta variant. In this work, we investigated the effectiveness of a single dose vaccine (Sputnik Light, the first component of Sputnik V vaccine) against the Delta variant in Moscow.

Methods

To assess the effectiveness of one dose of viral vector vaccine based on rAd26 against the delta variant in Moscow, we used data from the Moscow registries of vaccination against COVID-19 and the incidence of COVID-19. The availability of data on the number of seropositive residents of Moscow made it possible to consider the size of the immune layer formed because of a previous COVID-19 disease or vaccination. To calculate the effectiveness, the proportion of COVID-19 cases among those vaccinated with a single dose and the proportion of cases among those who were not vaccinated in July 2021.

Results

Our data indicate that throughout July 2021, the dominant variant of the coronavirus at the level of 99.5% in Moscow was the SARS-CoV-2 delta variant and its subsidiary lines. Considering the immune layer of 46% allowed us to calculate the effectiveness of a one-shot vaccine against the delta variant in Moscow during the first three months after vaccination at the level of 69.85% (95% confidence interval [CI], 64.08 to 74.70). In the 18-29-year-old group, the overall vaccine efficacy against the delta variant was 88.61%, in the 18-59 group - 75.28%. Sputnik Light demonstrates higher efficacy against Delta variant than many two-shot vaccines.

Conclusion

The results indicate a high efficacy of a single immunization first component of Sputnik V vaccine against delta variant among young and middle-aged people, at least during the first 3 months after receiving the one-shot vaccine.